Werewolf Therapeutics, Inc.
News
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the Company or Werewolf ) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of...\n more…
Research Analysts Offer Predictions for Werewolf Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:HOWL)
Ticker Report Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Werewolf Therapeutics in a research note issued on Monday, August...\n more…
Werewolf Therapeutics, Inc. to Post FY2024 Earnings of ($2.07) Per Share, Leerink Partnrs Forecasts (NASDAQ:HOWL)
Ticker Report Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Analysts at Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for Werewolf Therapeutics in a research note issued to...\n more…
Werewolf Therapeutics, Inc. Forecasted to Post Q3 2024 Earnings of ($0.45) Per Share (NASDAQ:HOWL)
Zolmax Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for Werewolf Therapeutics in a research note issued on...\n more…
Vanguard Group Inc. Purchases 233,909 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL)
Ticker Report Vanguard Group Inc. boosted its position in shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Free Report) by 26.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 1,107,347 shares...\n more…
HOWL Stock Earnings: Werewolf Therapeutics Misses EPS, Beats Revenue for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nHOWL stock results show that Werewolf Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second...\n more…